Targeting Epigenetic Resistance in Advanced Prostate Cancer: BET and DNMT Inhibition
E. David Crawford, MD, and Daniel P. Petrylak, MD, discuss BET and DNMT inhibition in lineage-plastic prostate cancer associated with TP53 or RB1 loss.
Read More
Metastatic Castration-Resistant (mCRPC)
Treatment after AR Pathway Inhibition (ARPI) + Radioligand Therapy (RLT)
Dr. Andrew W. Hahn reviews current treatment strategies after androgen receptor pathway inhibition and radioligand therapy, discussing sequencing challenges, molecular heterogeneity, biomarker-driven care, and emerging therapeutic approaches for advanced prostate cancer.
Read More
Immunotherapy When Nothing Else Works: Rational or Irrational Approach?
Dr. Susan F. Slovin explores why immunotherapy remains a promising strategy for selected patients with advanced prostate cancer, reviewing CAR T-cell therapy, bispecific T-cell engagers, emerging immune targets, and lessons from an exceptional clinical response.
Read More
Quality of Life, Adherence, and Adverse Events Among Patients with Advanced Prostate Cancer Treated with Relugolix: 6-Month Results of the OPTYX Multicenter Registry
Prospective OPTYX registry findings support relugolix adherence, safety, and quality of life.
Read More
Controversies with Testosterone Therapy
Dr. Khera reviews controversies in testosterone therapy, including prostate cancer, cardiovascular risk, and evolving treatment roles.
Read More